Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 299

1.

Impact of chronic migraine attacks and their severity on the endogenous μ-opioid neurotransmission in the limbic system.

Jassar H, Nascimento TD, Kaciroti N, DosSantos MF, Danciu T, Koeppe RA, Smith YR, Bigal ME, Porreca F, Casey KL, Zubieta JK, DaSilva AF.

Neuroimage Clin. 2019;23:101905. doi: 10.1016/j.nicl.2019.101905. Epub 2019 Jun 18.

2.

Fremanezumab as a preventive treatment for episodic and chronic migraine.

Bigal ME, Walter S, Rapoport AM.

Expert Rev Neurother. 2019 Aug;19(8):719-728. doi: 10.1080/14737175.2019.1614742. Epub 2019 May 22.

PMID:
31043094
3.

Painful Temporomandibular Disorder Is Associated With Migraine in Adolescents: A Case-Control Study.

Fernandes G, Arruda MA, Bigal ME, Camparis CM, Gonçalves DAG.

J Pain. 2019 Oct;20(10):1155-1163. doi: 10.1016/j.jpain.2019.03.010. Epub 2019 Mar 29.

PMID:
30936004
4.

Abuse-Deterrent OxyContin And Hepatitis C.

Bigal ME.

Health Aff (Millwood). 2019 Apr;38(4):696. doi: 10.1377/hlthaff.2019.00187. No abstract available.

PMID:
30933601
5.

The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment.

Silberstein SD, Rapoport AM, Loupe PS, Aycardi E, McDonald M, Yang R, Bigal ME.

Headache. 2019 Mar;59(3):383-393. doi: 10.1111/head.13446. Epub 2018 Nov 18.

PMID:
30450545
6.

From LBR-101 to Fremanezumab for Migraine.

Bigal ME, Rapoport AM, Silberstein SD, Walter S, Hargreaves RJ, Aycardi E.

CNS Drugs. 2018 Nov;32(11):1025-1037. doi: 10.1007/s40263-018-0579-4. Review.

PMID:
30311143
7.

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days.

VanderPluym J, Dodick DW, Lipton RB, Ma Y, Loupe PS, Bigal ME.

Neurology. 2018 Sep 18;91(12):e1152-e1165. doi: 10.1212/01.wnl.0000544321.19316.40. Epub 2018 Aug 17.

8.

Opioids vs Nonopioids for Chronic Back, Hip, or Knee Pain.

Bigal ME.

JAMA. 2018 Aug 7;320(5):507. doi: 10.1001/jama.2018.6949. No abstract available.

PMID:
30088004
9.

Do patients with migraine experience an increased prevalence of falls and fear of falling? A cross-sectional study.

Carvalho GF, Almeida CS, Florencio LL, Pinheiro CF, Dach F, Bigal ME, Bevilaqua-Grossi D.

Physiotherapy. 2018 Dec;104(4):424-429. doi: 10.1016/j.physio.2018.02.001. Epub 2018 Feb 15.

PMID:
29954585
10.

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853.

11.

Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials.

Halker Singh RB, Aycardi E, Bigal ME, Loupe PS, McDonald M, Dodick DW.

Cephalalgia. 2019 Jan;39(1):52-60. doi: 10.1177/0333102418772585. Epub 2018 May 3.

PMID:
29722276
12.

Presence of vestibular symptoms and related disability in migraine with and without aura and chronic migraine.

Carvalho GF, Vianna-Bell FH, Florencio LL, Pinheiro CF, Dach F, Bigal ME, Bevilaqua-Grossi D.

Cephalalgia. 2019 Jan;39(1):29-37. doi: 10.1177/0333102418769948. Epub 2018 Apr 10.

PMID:
29635938
13.

Recent advances in the management of chronic migraine in children.

Arruda MA, Chevis CF, Bigal ME.

Expert Rev Neurother. 2018 Mar;18(3):231-239. doi: 10.1080/14737175.2018.1438191. Epub 2018 Feb 10.

PMID:
29429363
14.

Fremanezumab for the Preventive Treatment of Chronic Migraine.

Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

N Engl J Med. 2017 Nov 30;377(22):2113-2122. doi: 10.1056/NEJMoa1709038.

15.

Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines.

Cohen JM, Dodick DW, Yang R, Newman LC, Li T, Aycardi E, Bigal ME.

Headache. 2017 Oct;57(9):1375-1384. doi: 10.1111/head.13156. Epub 2017 Sep 1.

PMID:
28862758
16.

Functional Balance Deterioration on Daily Activities in Patients With Migraine: A Controlled Study.

Carvalho GF, Florencio LL, Pinheiro CF, Dach F, Bigal ME, Bevilaqua-Grossi D.

Am J Phys Med Rehabil. 2018 Feb;97(2):90-95. doi: 10.1097/PHM.0000000000000793.

PMID:
28682840
17.

ADHD Is Comorbid to Migraine in Childhood: A Population-Based Study.

Arruda MA, Arruda R, Guidetti V, Bigal ME.

J Atten Disord. 2017 Jun 1:1087054717710767. doi: 10.1177/1087054717710767. [Epub ahead of print]

PMID:
28587507
18.

Association Between Severity of Temporomandibular Disorders and the Frequency of Headache Attacks in Women With Migraine: A Cross-Sectional Study.

Florencio LL, de Oliveira AS, Carvalho GF, Dach F, Bigal ME, Fernández-de-Las-Peñas C, Bevilaqua-Grossi D.

J Manipulative Physiol Ther. 2017 May;40(4):250-254. doi: 10.1016/j.jmpt.2017.02.006. Epub 2017 Apr 6.

PMID:
28390711
19.

Cutaneous allodynia is more frequent in chronic migraine, and its presence and severity seems to be more associated with the duration of the disease.

Benatto MT, Florencio LL, Carvalho GF, Dach F, Bigal ME, Chaves TC, Bevilaqua-Grossi D.

Arq Neuropsiquiatr. 2017 Mar;75(3):153-159. doi: 10.1590/0004-282X20170015.

20.

Anxiety and depression symptoms and migraine: a symptom-based approach research.

Peres MFP, Mercante JPP, Tobo PR, Kamei H, Bigal ME.

J Headache Pain. 2017 Dec;18(1):37. doi: 10.1186/s10194-017-0742-1. Epub 2017 Mar 21.

21.

Balance Impairments in Different Subgroups of Patients With Migraine.

Carvalho GF, Bonato P, Florencio LL, Pinheiro CF, Dach F, Bigal ME, Bevilaqua-Grossi D.

Headache. 2017 Mar;57(3):363-374. doi: 10.1111/head.13009. Epub 2016 Dec 19.

PMID:
27991667
22.

Primary Headaches in an Elderly Population Seeking Medical Care for Cognitive Decline.

Feleppa M, Fucci S, Bigal ME.

Headache. 2017 Feb;57(2):209-216. doi: 10.1111/head.13003. Epub 2016 Dec 9.

PMID:
27933636
23.

Obesity as a risk factor for temporomandibular disorders.

Jordani PC, Campi LB, Circeli GZ, Visscher CM, Bigal ME, Gonçalves DA.

J Oral Rehabil. 2017 Jan;44(1):1-8. doi: 10.1111/joor.12453. Epub 2016 Nov 13.

PMID:
27748537
24.

A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients.

Gutman D, Hellriegel E, Aycardi E, Bigal ME, Kunta J, Chitra R, Kansagra S, Kidron OS, Knebel H, Linder S, Ma Y, Pierce M, Winner PK, Spiegelstein O.

Headache. 2016 Sep;56(8):1300-9. doi: 10.1111/head.12895. Epub 2016 Jul 29.

PMID:
27474357
25.

Patients with chronic, but not episodic, migraine display altered activity of their neck extensor muscles.

Florencio LL, Oliveira AS, Lemos TW, Carvalho GF, Dach F, Bigal ME, Falla D, Fernández-de-Las-Peñas C, Bevilaqua-Grossi D.

J Electromyogr Kinesiol. 2016 Oct;30:66-72. doi: 10.1016/j.jelekin.2016.06.003. Epub 2016 Jun 9.

PMID:
27317975
26.

TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points.

Bigal ME, Dodick DW, Krymchantowski AV, VanderPluym JH, Tepper SJ, Aycardi E, Loupe PS, Ma Y, Goadsby PJ.

Neurology. 2016 Jul 5;87(1):41-8. doi: 10.1212/WNL.0000000000002801. Epub 2016 Jun 8.

27.

Concomitant Migraine and Temporomandibular Disorders are Associated With Higher Heat Pain Hyperalgesia and Cephalic Cutaneous Allodynia.

Chaves TC, Dach F, Florencio LL, Carvalho GF, Gonçalves MC, Bigal ME, Speciali JG, Bevilaqua-Grossi D.

Clin J Pain. 2016 Oct;32(10):882-8. doi: 10.1097/AJP.0000000000000369.

PMID:
26905569
28.

Reduced thermal threshold in patients with Temporomandibular Disorders.

Carvalho GF, Chaves TC, Florencio LL, Dach F, Bigal ME, Bevilaqua-Grossi D.

J Oral Rehabil. 2016 Jun;43(6):401-8. doi: 10.1111/joor.12386. Epub 2016 Feb 12.

PMID:
26871585
29.

Additional Effects of a Physical Therapy Protocol on Headache Frequency, Pressure Pain Threshold, and Improvement Perception in Patients With Migraine and Associated Neck Pain: A Randomized Controlled Trial.

Bevilaqua-Grossi D, Gonçalves MC, Carvalho GF, Florencio LL, Dach F, Speciali JG, Bigal ME, Chaves TC.

Arch Phys Med Rehabil. 2016 Jun;97(6):866-74. doi: 10.1016/j.apmr.2015.12.006. Epub 2015 Dec 21.

PMID:
26718237
30.

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB.

Lancet Neurol. 2015 Nov;14(11):1081-90. doi: 10.1016/S1474-4422(15)00249-5. Epub 2015 Sep 30.

PMID:
26432182
31.

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD.

Lancet Neurol. 2015 Nov;14(11):1091-100. doi: 10.1016/S1474-4422(15)00245-8. Epub 2015 Sep 30.

PMID:
26432181
32.

Cervical Muscle Strength and Muscle Coactivation During Isometric Contractions in Patients With Migraine: A Cross-Sectional Study.

Florencio LL, de Oliveira AS, Carvalho GF, Tolentino Gde A, Dach F, Bigal ME, Fernández-de-las-Peñas C, Bevilaqua Grossi D.

Headache. 2015 Nov-Dec;55(10):1312-22. doi: 10.1111/head.12644. Epub 2015 Sep 21.

PMID:
26388193
33.

Study of the use of analgesics by patients with headache at a specialized outpatient clinic (ACEF).

Chagas OF, Éckeli FD, Bigal ME, Silva MO, Speciali JG.

Arq Neuropsiquiatr. 2015 Jul;73(7):586-92. doi: 10.1590/0004-282X20150072.

34.

Sumatriptan Iontophoretic Transdermal System Reduces Treatment-Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline - Results From a Randomized Controlled Trial.

Bigal ME, Lipton RB, Newman LC, Pierce MW, Silberstein SD.

Headache. 2015 Sep;55(8):1124-32. doi: 10.1111/head.12606. Epub 2015 Jul 14. Erratum in: Headache. 2015 Nov;55(10):1479.

PMID:
26178815
35.

Cerebral Venous Thrombosis and Headache--A Case-Series.

Sparaco M, Feleppa M, Bigal ME.

Headache. 2015 Jun;55(6):806-14. doi: 10.1111/head.12599.

PMID:
26084237
36.

TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine.

Walter S, Bigal ME.

Curr Pain Headache Rep. 2015 Mar;19(3):6. doi: 10.1007/s11916-015-0476-1. Review.

PMID:
25754596
37.

Psychosocial adjustment of children with migraine and tension-type headache - a nationwide study.

Arruda MA, Arruda R, Guidetti V, Bigal ME.

Headache. 2015 Feb;55 Suppl 1:39-50. doi: 10.1111/head.12510. Epub 2015 Feb 6.

PMID:
25659227
38.

Therapeutic antibodies against CGRP or its receptor.

Bigal ME, Walter S, Rapoport AM.

Br J Clin Pharmacol. 2015 Jun;79(6):886-95. doi: 10.1111/bcp.12591. Review.

39.

Association between tension-type headache and migraine with sleep bruxism: a systematic review.

De Luca Canto G, Singh V, Bigal ME, Major PW, Flores-Mir C.

Headache. 2014 Oct;54(9):1460-9. doi: 10.1111/head.12446. Epub 2014 Sep 18. Review.

PMID:
25231339
40.

Commentary on Westergaard's "Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: A systematic review".

Rapoport AM, Meskunas CA, Bigal ME.

Cephalalgia. 2015 Jun;35(7):637-8. doi: 10.1177/0333102414547783. Epub 2014 Aug 28. No abstract available.

PMID:
25169733
41.

Endoscopic sinus surgery in individuals with facial pain due to chronic maxillary sinusitis - a functional controlled study.

Sanges G, Gamerra M, Sorrentino G, De Luca R, Merone M, Feleppa M, Bigal ME.

Arq Neuropsiquiatr. 2014 Aug;72(8):609-12. Epub 2014 Jul 4.

42.

Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide.

Walter S, Alibhoy A, Escandon R, Bigal ME.

MAbs. 2014 Jul-Aug;6(4):871-8. doi: 10.4161/mabs.29242. Epub 2014 May 21.

43.

Neck pain disability is related to the frequency of migraine attacks: a cross-sectional study.

Florencio LL, Chaves TC, Carvalho GF, Gonçalves MC, Casimiro EC, Dach F, Bigal ME, Bevilaqua-Grossi D.

Headache. 2014 Jul-Aug;54(7):1203-10. doi: 10.1111/head.12393. Epub 2014 May 26.

PMID:
24863346
44.

Clinical trials update - 2013: year in review.

Bigal ME.

Headache. 2014 Apr;54(4):756. doi: 10.1111/head.12313. No abstract available.

PMID:
24697232
45.

The vasodilatory activity of CGRP: a response.

Bigal ME, Walter S, Rapoport AM.

Headache. 2014 Apr;54(4):748-9. doi: 10.1111/head.12316. No abstract available.

PMID:
24697226
46.

Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP.

Bigal ME, Walter S, Bronson M, Alibhoy A, Escandon R.

Cephalalgia. 2014 Oct;34(12):968-76. doi: 10.1177/0333102414527646. Epub 2014 Mar 24.

PMID:
24662322
47.

Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.

Bigal ME, Walter S.

CNS Drugs. 2014 May;28(5):389-99. doi: 10.1007/s40263-014-0156-4. Review.

PMID:
24638916
48.

Headache classification and aspects of reproductive life in young women.

Melhado EM, Bigal ME, Galego AR, Galdezzani JP, Queiroz LP.

Arq Neuropsiquiatr. 2014 Jan;72(1):17-23. doi: 10.1590/0004-282X20130188.

49.

Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program.

Bigal ME, Escandon R, Bronson M, Walter S, Sudworth M, Huggins JP, Garzone P.

Cephalalgia. 2014 Jun;34(7):483-92. doi: 10.1177/0333102413517775. Epub 2013 Dec 23.

PMID:
24366980
50.

Treatment of comorbid migraine and temporomandibular disorders: a factorial, double-blind, randomized, placebo-controlled study.

Goncalves DA, Camparis CM, Speciali JG, Castanharo SM, Ujikawa LT, Lipton RB, Bigal ME.

J Orofac Pain. 2013 Fall;27(4):325-35. doi: 10.11607/jop.1096.

PMID:
24171182

Supplemental Content

Loading ...
Support Center